Table 2.
Effect of probiotic (B. subtilis CU1) and placebo consumption on clinical outcomes of infectious diseases
| Whole population (N = 100) | Subset of population (N = 44) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Probiotic group (N = 50) | Placebo group (N = 50) | P | Probiotic group (N = 22) | Placebo group (N = 22) | P | |||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | |||
| Mean number of days with CID | 5.1 | 7.0 | 6.6 | 7.3 | 0.2015a | 4.5 | 7.3 | 7.3 | 8.2 | 0.1101a |
| Mean duration of CID (d) | 5.0 | 4.6 | 5.3 | 4.1 | 0.2361a | 5.8 | 5.6 | 5.7 | 4.1 | 0.2361a |
| Mean intensity of CID | 8.1 | 5.0 | 7.6 | 4.4 | 0.7400a | 9.0 | 6.2 | 8.8 | 5.3 | 0.7400a |
| CID frequency | 1.0 | 1.2 | 1.2 | 1.2 | 0.3290a | 0.8 | 1.0 | 1.3 | 1.2 | 0.1117a |
| Subjects with at least one CID | 0.4106b | 0.1260b | ||||||||
| n | 29 | 33 | 11 | 16 | ||||||
| % | 58 · 0 | 66 · 0 | 50 · 0 | 72 · 7 | ||||||
| Mean number of days with RI | 4.4 | 6.9 | 6.2 | 7.2 | 0.1027a | 3.7 | 6.9 | 6.6 | 7.9 | 0.0818a |
| Mean duration of RI (d) | 5.9 | 5.0 | 5.6 | 4.2 | 0.9043a | 6.8 | 6.3 | 6.1 | 4.3 | 0.9325a |
| Mean intensity of RI | 9.3 | 5.3 | 7.8 | 4.6 | 0.1428a | 11.1 | 6.3 | 9.3 | 5.6 | 0.3473a |
| RI frequency | 0.7 | 0.9 | 1.1 | 1.2 | 0.1181a | 0.6 | 0.7 | 1.1 | 0.9 | 0.0323 a |
| Subjects with at least one RI | 0.1609b | 0.0701b | ||||||||
| n | 24 | 31 | 10 | 16 | ||||||
| % | 48.0 | 62.0 | 45.5 | 72.7 | ||||||
Data are presented for the whole population (N = 100) and the subset of population with biology analysis (N = 44). (Mean values and standard deviations; numbers and percentages)
Statistical differences were evaluated using Wilcoxon-Mann-Whitney’s test or Savage’s test according to the asymmetry of data (a), or logistic regression model (b)